CONTENTS

6 OVERVIEW

6 Latest key takeaways

8 DISEASE BACKGROUND

8 Definition

8 Symptoms

8 Diagnosis

8 Risk factors

10 VACCINATION GUIDELINES

10 Vaccination guidelines in major markets

13 MARKETED VACCINES

15 PIPELINE VACCINES

19 KEY REGULATORY EVENTS

19 UK Adds Pneumococcal Polysaccharide Vaccine To Export Ban List

20 PROBABILITY OF SUCCESS

21 CLINICAL TRIAL LANDSCAPE

22 Sponsors by status

23 Sponsors by phase

24 Recent events

25 VACCINE ASSESSMENT

25 Prevnar 13

25 Pneumovax 23

26 V114

26 PF-06482077

28 MARKET DYNAMICS

29 FUTURE TRENDS

30 CONSENSUS FORECASTS

31 RECENT EVENTS AND ANALYST OPINION

31 V114 for Pneumococcal Vaccines (June 22, 2020)

32 PF-06482077 for Pneumococcal Vaccines (March 18, 2020)

33 V114 for Pneumococcal Vaccines (May 8, 2019)

35 KEY UPCOMING EVENTS

36 KEY OPINION LEADER INSIGHTS

37 UNMET NEEDS

37 Vaccines with broader serotype coverage to counter the threat of serotype shift

37 Low coverage in miscellaneous “at-risk” groups

38 BIBLIOGRAPHY

38 Prescription information

40 APPENDIX

LIST OF FIGURES

15 Figure 1: Overview of pipeline pneumococcal vaccines in the US

15 Figure 2: Pipeline pneumococcal vaccines, by company

16 Figure 3: Pipeline pneumococcal vaccines, by drug type

16 Figure 4: Pipeline pneumococcal vaccines, by classification

20 Figure 5: Probability of success in the pneumococcal vaccines pipeline

21 Figure 6: Clinical trials in pneumococcal vaccines and therapeutic agents

21 Figure 7: Top 10 drugs for clinical trials in pneumococcal vaccines and therapeutic agents

22 Figure 8: Top 10 companies for clinical trials in pneumococcal vaccines and therapeutic agents

22 Figure 9: Trial locations in pneumococcal vaccines and therapeutic agents

23 Figure 10: Pneumococcal vaccines and therapeutic agents trials status

24 Figure 11: Pneumococcal vaccines and therapeutic agents, by phase

28 Figure 12: Market dynamics in pneumococcal vaccines

29 Figure 13: Future trends in pneumococcal vaccines

32 Figure 14: V114 for Pneumococcal Vaccines (June 22, 2020): Phase III - PNEU-WAY / PNEU-FLU

35 Figure 15: Key upcoming events in pneumcoccal vaccines

LIST OF TABLES

11 Table 1: Vaccination guidelines in major markets

14 Table 2: Marketed pneumococcal vaccines

17 Table 3: Pipeline pneumococcal vaccines in the US

30 Table 4: Historical global sales, by vaccine ($m), 2015–19

30 Table 5: Forecasted global sales, by vaccine ($m), 2020–24

31 Table 6: V114 for Pneumococcal Vaccines (June 22, 2020)

33 Table 7: PF-06482077 for Pneumococcal Vaccines (March 18, 2020)
34 Table 8: V114 for Pneumococcal Vaccines (May 8, 2019)